While SARM1 mutations have started to be identified as contributary to neurological diseases such as ALS (Gilley et al., 2021; Bloom et al., 2022), the question of whether SARM1 mutants are solely pathological in neurons or whether their expression in glia, such as astrocytes and oligodendrocytes, is contributary to the pathology, is now particularly pertinent. This evidence concerns the gene SARM1 and amyotrophic lateral sclerosis.